Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 29, Number 1—January 2023
Research

High SARS-CoV-2 Seroprevalence after Second COVID-19 Wave (October 2020–April 2021), Democratic Republic of the Congo

Yannick Munyeku-Bazitama, Gervais T. Folefack, Marc K. Yambayamba, Paul M. Tshiminyi, Benito M. Kazenza, John O. Otshudiema, Noe Tondri Guinko, Moreau D. Umba, Anastasie Mulumba, Lionel K. Baketana, Patrick K. Mukadi, Chris Smith, Jean-Jacques Muyembe-Tamfum, Steve Ahuka-Mundeke, and Sheila Makiala-MandandaComments to Author 
Author affiliations: Hokkaido University, Sapporo, Japan (Y. Munyeku-Bazitama); Université de Kinshasa, Kinshasa (Y. Munyeku-Bazitama, M.K. Yambayamba, B.M. Kazenza, P.K. Mukadi, J.-J. Muyembe-Tamfum, S. Ahuka-Mundeke, S. Makiala-Mandanda); Institut National de Recherche Biomédicale, Kinshasa, Democratic Republic of the Congo (Y. Munyeku-Bazitama, P.M. Tshiminyi, L.K. Baketana, P.K. Mukadi, J.-J. Muyembe-Tamfum, S. Ahuka-Mundeke, S. Makiala-Mandanda); Organisation Mondiale de la Santé, Kinshasa (G.T. Folefack, J.O. Otshudiema, N. Tondri Guinko, M.D. Umba, A. Mulumba); Nagasaki University, Japan (P.K. Mukadi, C. Smith); London School of Hygiene and Tropical Medicine, London, UK (C. Smith)

Main Article

Table 2

Clinical characteristics of 2,560 study participants in a study to ascertain cumulative SARS-CoV-2 exposure in Kinshasa, Democratic Republic of the Congo, after the second COVID-19 wave*

Variables Value
Symptoms suggestive of COVID-19 2 weeks before survey
N 1,280 (50.0)
Y 1,280 (50.0)
Fever 713 (27.8)
Headaches 627 (24.5)
Chills 423 (16.5)
Fatigue 409 (15.9)
Coughing 400 (15.6)
Runny nose 369 (14.4)
Myalgia 363 (14.2)
Abdominal pain 214 (8.4)
Sore throat 134 (5.2)
Nausea 132 (5.2)
Diarrhea 125 (4.9)
Anosmia/ageusia 83 (3.2)
Chest pain 73 (2.9)
Dyspnea 57 (2.2)
Median (IQR) no. symptoms
 3 (1–4)
Comorbidity
N 2,252 (88.0)
Y
 308 (12.0)
Hypertension
N 2,394 (93.5)
Y
 166 (6.5)
Stroke
N 2,540 (99.2)
Y
 20 (0.8)
Asthma
N 2,521 (98.5)
Y
 39 (1.5)
Diabetes mellitus
N 2,532 (98.9)
Y
 28 (1.1)
Kidney injury
N 2,553 (99.7)
Y
 7 (0.3)
Cancer
N 2,554 (99.8)
Y
 6 (0.2)
Obesity
N 2,464 (96.3)
Y
 96 (3.7)
Pregnancy†
N 1,371 (97.1)
Y
 41 (2.9)
Contact with a laboratory-confirmed case
N 2,493 (97.4)
Y 67 (2.6)

*Values are no. (%) except as indicated. IQR interquartile range. †Only women were considered for pregnancy.

Main Article

Page created: November 15, 2022
Page updated: December 21, 2022
Page reviewed: December 21, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external